- Home
- CNTB vs SPRO Comparison
CNTB vs SPRO Comparison
Compare CNTB & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- SPRO
- Stock Information
- Founded
- CNTB 2012
- SPRO 2013
- Country
- CNTB United States
- SPRO United States
- Employees
- CNTB N/A
- SPRO 32
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- SPRO Health Care
- Exchange
- CNTB Nasdaq
- SPRO Nasdaq
- Market Cap
- CNTB 43.2M
- SPRO 33.0M
- IPO Year
- CNTB 2021
- SPRO 2017
- Fundamental
- Price
- CNTB $0.78
- SPRO $0.69
- Analyst Decision
- CNTB Strong Buy
- SPRO Buy
- Analyst Count
- CNTB 1
- SPRO 4
- Target Price
- CNTB $8.00
- SPRO $5.00
- AVG Volume (30 Days)
- CNTB 212.7K
- SPRO 111.2K
- Earning Date
- CNTB 03-31-2025
- SPRO 05-13-2025
- Dividend Yield
- CNTB N/A
- SPRO N/A
- EPS Growth
- CNTB N/A
- SPRO N/A
- EPS
- CNTB N/A
- SPRO N/A
- Revenue
- CNTB $26,033,000.00
- SPRO $47,977,000.00
- Revenue This Year
- CNTB N/A
- SPRO N/A
- Revenue Next Year
- CNTB N/A
- SPRO N/A
- P/E Ratio
- CNTB N/A
- SPRO N/A
- Revenue Growth
- CNTB N/A
- SPRO N/A
- 52 Week Low
- CNTB $0.51
- SPRO $0.51
- 52 Week High
- CNTB $2.08
- SPRO $1.72
- Technical
- Relative Strength Index (RSI)
- CNTB 50.56
- SPRO 53.47
- Support Level
- CNTB $0.76
- SPRO $0.57
- Resistance Level
- CNTB $0.85
- SPRO $0.70
- Average True Range (ATR)
- CNTB 0.05
- SPRO 0.04
- MACD
- CNTB -0.00
- SPRO 0.01
- Stochastic Oscillator
- CNTB 26.00
- SPRO 67.04
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.